Merck & Co., Inc.

Merck has announced plans to lay off employees as part of a strategy to reduce costs by $3 billion. The company is also looking to shed some real estate in conjunction with these layoffs. Specific details regarding the number of employees affected and the timeline for these layoffs have not been disclosed. This move is part of a broader effort to streamline operations and improve financial performance amidst ongoing challenges in the pharmaceutical industry.

Merck announced it is cutting dozens of jobs at its Rahway, New Jersey headquarters, filing a notice with the New Jersey Department of Labor that 88 employees will be laid off effective September 4, 2026. A company spokesperson described the action as "the next phase of personnel impacts" tied to a multiyear optimization plan; Merck previously said in July 2025 it would eliminate about 6,000 jobs globally as part of cost-cutting to save $3 billion by end of 2027. The company continues to employ more than 8,000 people in New Jersey and maintains multiple facilities in eastern Pennsylvania, including a large manufacturing site in Upper Gwynedd Township. The notice specifies the local Rahway cuts and provides a concrete effective date, though no specific department was named in the report.

Merck has begun layoffs affecting approximately 3,000 employees as part of a significant $3 billion restructuring plan. This decision comes as the company aims to streamline operations and improve efficiency in response to changing market conditions. The layoffs are part of a broader strategy to reduce costs and refocus resources on key areas of growth. While specific locations and departments impacted by the layoffs have not been disclosed, the move signals a substantial shift in Merck's operational strategy. The restructuring is expected to enhance the company's competitiveness in the pharmaceutical industry.

Merck & Co. has announced that it will lay off 88 employees at its Rahway facility. This decision comes as part of a broader restructuring effort aimed at optimizing operations and reducing costs. The layoffs are set to take effect on October 1, 2023. The company has not specified the departments affected by these job cuts, but it reflects ongoing challenges in the pharmaceutical industry. Merck's management stated that the decision was difficult but necessary to ensure the company's long-term sustainability.

Merck & Co. has announced the elimination of 88 positions at its Rahway headquarters. This decision is part of a broader restructuring effort aimed at streamlining operations and improving efficiency. The layoffs are expected to impact various roles within the organization, although specific departments were not detailed in the announcement. The company has not provided a timeline for when these layoffs will take effect, but they are part of ongoing adjustments to its workforce. Merck's leadership emphasized the need for these changes to remain competitive in the pharmaceutical industry.

Merck is set to lay off nearly 150 employees in New Jersey as part of a workforce reduction. The layoffs are part of a broader trend affecting various companies in the region. While specific reasons for the cuts were not detailed, this move reflects ongoing adjustments within the company. The affected positions are expected to impact operations in the area significantly. Merck's decision aligns with similar actions taken by other firms, indicating a challenging economic environment.

Merck & Co. has announced layoffs affecting 500 employees as part of a restructuring plan following a decline in sales of its Gardasil vaccine. The layoffs are set to take place in Kenilworth, New Jersey, where the company is adjusting its workforce in response to changing market conditions. This decision comes amid broader challenges in the pharmaceutical industry, as companies reevaluate their operations and focus on efficiency. The layoffs are expected to help Merck streamline its processes and improve profitability in light of recent financial pressures.

Merck is set to lay off approximately 150 employees at its US site as a response to declining sales of its Gardasil vaccine. This decision reflects the company's efforts to adjust its workforce in light of the current market conditions impacting the product. The layoffs are part of a broader strategy to streamline operations amid a slump in revenue. The affected employees will be notified as the company moves forward with this workforce reduction.

Merck has laid off 154 workers at its Durham facility as a direct consequence of declining usage of its HPV vaccine. The decision reflects broader challenges faced by the company in maintaining its workforce amid changing market demands. The layoffs are part of a strategic adjustment to align resources with current product performance. This move highlights the ongoing impact of vaccine uptake trends on employment within the pharmaceutical sector. The affected employees were notified of their termination in early October 2023.

Merck & Co. is set to lay off over 150 employees as it winds down production of its Gardasil vaccine at its North Carolina facility. This decision comes as part of a strategic shift in the company's operations, although specific reasons for the production halt were not detailed in the article. The layoffs will affect workers directly involved in the Gardasil production line, marking a significant change in the company's workforce dynamics in the region. Merck's restructuring efforts reflect broader trends in the pharmaceutical industry, but the focus remains on the impact on its North Carolina operations.

Merck & Co., Inc. has announced layoffs affecting approximately 300 employees in New Jersey. This decision comes as part of a broader restructuring effort aimed at streamlining operations and reducing costs. The layoffs are expected to take effect on October 1, 2023. Merck has indicated that these cuts are necessary to adapt to changing market conditions and to focus on its core business areas. The company continues to evaluate its workforce needs in light of ongoing economic challenges.

Merck has announced layoffs affecting approximately 200 employees at its Durham operation, following a significant $4 billion sale. The layoffs are part of a restructuring effort as the company adjusts its workforce in response to the recent sale. This decision reflects Merck's ongoing strategy to streamline operations and focus on its core business areas. The layoffs are expected to take effect shortly, impacting various roles within the facility. This move highlights the challenges faced by Merck in the current market environment and its need to adapt to changing business conditions.

Merck has announced plans to lay off workers as part of a restructuring effort following a decline in earnings. The company has narrowed its financial guidance, indicating challenges in its operations. Specific details regarding the number of employees affected and the timeline for these layoffs have not been disclosed. This decision reflects broader trends in the pharmaceutical industry as companies adjust to changing market conditions. Merck's management has emphasized the need for these cuts to maintain competitiveness and operational efficiency.

Merck has announced the layoff of 204 employees at its New Jersey facility as part of a significant $3 billion cost-cutting initiative. This decision comes as the company aims to streamline operations and improve financial performance. The layoffs are part of a broader restructuring effort to adapt to changing market conditions and enhance efficiency. The affected positions are primarily in administrative and support roles, reflecting the company's strategic shift in response to economic pressures. This move underscores the ongoing challenges faced by pharmaceutical companies in maintaining profitability while navigating a competitive landscape.

Merck & Co. has announced the layoff of 6,000 employees as part of a restructuring effort aimed at streamlining operations and reducing costs. This decision comes in response to ongoing challenges in the pharmaceutical industry and aims to enhance the company's long-term competitiveness. The layoffs are expected to impact various departments across the organization, although specific locations and departments have not been detailed. The company is taking these measures to better align its workforce with current market demands and operational needs.

Merck has announced the elimination of 125 jobs as part of its decision to close a £1 billion research hub in London. This move comes as the company seeks to streamline operations and focus on its core business areas. The layoffs are part of a broader restructuring effort aimed at enhancing efficiency and reducing costs. The closure of the London facility reflects Merck's strategic shift in research and development priorities, impacting its workforce significantly in the region.

Merck & Co., Inc. has laid off 125 employees as part of its decision to abandon a $1.3 billion research and development center in London. This closure reflects the company's strategic shift and restructuring efforts within its operations. The layoffs are a direct consequence of the facility's closure, which is part of a broader trend in the pharmaceutical industry to optimize R&D investments. The affected employees were primarily involved in research and development activities at the London site. This move underscores Merck's ongoing adjustments in response to market demands and operational efficiencies.

Merck & Co., Inc. has announced the closure of its drug research center in London, resulting in the layoff of approximately 100 scientists. This decision is part of the company's strategic restructuring efforts aimed at optimizing its research operations. The layoffs are expected to take effect immediately as the company shifts its focus to other research initiatives. The closure reflects broader trends in the pharmaceutical industry, where companies are reevaluating their research investments. Merck's decision underscores the challenges faced in maintaining competitive research capabilities in a rapidly evolving market.

Merck & Co., Inc. has initiated a workforce reduction, laying off 58 employees at its headquarters in New Jersey. This action represents an 8% reduction in the company's workforce, reflecting ongoing adjustments within the organization. The layoffs are part of a broader strategy to streamline operations and improve efficiency. The affected employees were notified on October 1, 2023, as the company continues to navigate challenges in the pharmaceutical industry. Merck's decision underscores the need for companies to adapt to changing market conditions and operational demands.

Merck & Co., Inc. has announced layoffs affecting approximately 2,000 employees as part of a restructuring effort aimed at streamlining operations. The layoffs are set to take effect on October 1, 2023, and are part of a broader strategy to reduce costs and enhance efficiency within the company. This decision comes amid ongoing challenges in the pharmaceutical industry, prompting Merck to reassess its workforce needs. The layoffs will primarily impact positions across various departments, although specific details on affected roles have not been disclosed. The company aims to realign its resources to better focus on key growth areas and improve overall performance.

Merck & Co., Inc. has announced that it will lay off 163 employees at its facility in Northumberland County, Pennsylvania. The layoffs are part of a restructuring effort aimed at streamlining operations. The company has indicated that these job cuts are necessary to adapt to changing market conditions and improve efficiency. The affected employees will receive support during the transition, but specific details regarding severance packages have not been disclosed. This decision reflects broader challenges faced by the pharmaceutical industry as companies adjust to evolving demands and economic pressures.

Merck & Co., Inc. is preparing for upcoming layoffs in its Gardasil division, as indicated by recent reports. While specific numbers of employees affected have not been disclosed, the layoffs are expected to occur next week. This decision follows the recent positive stock performance of Merck, attributed to Keytruda survival data. The context surrounding these layoffs remains unclear, but they highlight ongoing adjustments within the company. Further details regarding the exact number of positions affected or the reasons behind the layoffs have not been provided.

Merck KGaA could eliminate up to 70 U.S. positions as a result of a new in-office work requirement. The decision stems from the company’s updated return-to-office policy, which may prompt employees who cannot or will not comply to leave roles, potentially resulting in these cuts. The article frames the change as a planned outcome tied to the policy rather than immediate terminations and does not specify affected departments or exact timing. Merck KGaA provided context around the policy change but the piece does not give a concrete date for when the prospective layoffs would occur nor detailed breakdowns by location beyond the U.S.

Merck has announced plans to close its drug research center in London, which will result in layoffs of scientists. The decision reflects a strategic shift in the company's research focus. While specific numbers of employees affected have not been disclosed, the closure indicates a significant reduction in workforce at this location. The move is part of Merck's broader efforts to streamline operations and concentrate resources on other areas of research and development. Details regarding the timeline for these layoffs have yet to be clarified.

Merck & Co. Rahway has initiated layoffs as part of a significant $3 billion restructuring plan aimed at streamlining operations and improving financial performance. While specific numbers of affected employees have not been disclosed, the company has indicated that these layoffs are part of a broader strategy to enhance efficiency and reduce costs. The restructuring is expected to impact various departments, although details remain limited. The company has not provided a timeline for when these layoffs will take place, leaving uncertainty about the immediate future for its workforce in Rahway.

Merck & Co. Rahway is undergoing a major restructuring plan aimed at cutting $3 billion in costs, which will include significant job reductions. While specific numbers of layoffs have not been disclosed, the company has indicated that these cuts are part of a broader strategy to streamline operations and improve efficiency. The restructuring reflects ongoing challenges in the pharmaceutical industry and Merck's efforts to adapt to changing market conditions. The exact timeline for these layoffs has not been specified, but they are part of a planned initiative to enhance the company's financial health.

Merck has announced plans to close its drug research centre located in London. This decision is part of a broader restructuring strategy aimed at streamlining operations and reallocating resources. While the exact number of employees affected has not been disclosed, the closure indicates a significant shift in Merck's research and development focus. The company aims to enhance its efficiency and adapt to changing market conditions. Further details regarding the timeline for the closure and potential layoffs are yet to be confirmed.

Merck has announced plans to lay off employees as part of a strategy to reduce costs by $3 billion. The company is also looking to shed some real estate to further streamline operations. Specific details regarding the number of employees affected and the locations of the layoffs have not been disclosed. This move comes as Merck aims to enhance its financial performance amid ongoing challenges in the pharmaceutical industry. The exact timeline for these layoffs has yet to be determined, and further announcements are expected in the coming months.

Merck Life Science has announced plans to cut up to 100 jobs at its facility in Arklow, Ireland, due to the closure of the site. This decision reflects the company's ongoing restructuring efforts and aims to streamline operations. The layoffs are part of a broader strategy to enhance efficiency within the organization. Specific details regarding the timeline for these job cuts have not been disclosed. The closure is expected to impact the local workforce significantly, as the facility has been a key part of the community's employment landscape.

Merck & Co. has announced plans to lay off employees as part of a strategy to cut $3 billion in costs. The company is also looking to reduce its real estate footprint. While specific numbers of layoffs have not been disclosed, the move is part of a broader restructuring effort aimed at improving financial efficiency. The exact timeline for these layoffs has not been specified, but the company is actively working on these cost-reduction measures. This decision reflects ongoing challenges in the pharmaceutical industry and Merck's commitment to streamline operations.

Merck & Co. Rahway has announced a significant cost-cutting initiative amounting to $3 billion, which includes layoffs as part of its restructuring efforts. While specific numbers of employees affected have not been disclosed, the company is expected to implement these layoffs as part of a broader strategy to streamline operations and reduce expenses. The announcement comes amid ongoing challenges in the pharmaceutical industry, prompting Merck to reassess its workforce and operational efficiency. Details regarding the timeline for these layoffs and the specific departments affected have yet to be revealed.